News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pivotal Therapeutics Inc. Engages Brandkarma LLC.


5/14/2014 10:23:17 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WOODBRIDGE, ON, May 13, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced that it has engaged Brandkarma LLC., an award winning, US-based, healthcare marketing and brand specialist with global expertise to support the Company's commercialization strategy for VASCAZEN®.

"VASCAZEN® represents a much-needed solution for Omega-3 deficiency. Healthcare providers and the general public at large need to know the serious health risks associated with this deficiency. We are proud to be a part of the team tasked with bringing this brand to the market," stated Ken Ribotsky, President and CEO of Brandkarma. Brandkarma's client list includes some of the largest healthcare companies in the world and has established itself as a leader in the medical food arena.

"We are very excited to have Brandkarma as our marketing partner," stated Ms. Rachelle MacSweeney, President and COO. "With the closing of the financing on March 4, Pivotal finally has the resources to execute its marketing plan and implement its strategy to effectively penetrate US market opportunities for VASCAZEN®. We would also like to thank our investors and shareholders for their continued support and patience as we embark on this next stage of commercialization and make VASCAZEN® a success," added Ms. Rachelle MacSweeney, President and COO.

About VASCAZEN®

VASCAZEN® is currently available in the U.S. as a prescription only medical food specifically formulated for the dietary management of an Omega-3 deficiency in cardiovascular patients. VASCAZEN® is a >90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid formulation, protected by a series of both U.S. and foreign patents.

VASCAZEN® has been clinically shown to correct an Omega-3 deficiency within eight weeks of treatment with positive concomitant effects on the lipid profiles, mainly a 48% reduction of triglycerides and an increase of HDL without negative impact on the LDL-C lipid profile. VASCAZEN®'s results were achieved with a dose of 3 grams of EPA and DHA per day of a prescription grade, high purity Omega-3.

About Brandkarma LLC.

Brandkarma LLC. is a strategic marketing consulting and healthcare communications company for specialty pharmaceutical, biotech, medical device, diagnostic and health service companies. Clients collaborate with Brandkarma's highly specialized and experienced strategists to tackle everything from brand (re)positioning and market landscaping to strategic and creative brand development, advertising and promotion, sales force programs, corporate communications, corporate identity, digital and social media, and public relations. Learn more about Brandkarma at the award-winning website brandkarma.org.

About Pivotal Therapeutics Inc.

Pivotal Therapeutics is a publicly traded (OTCQX: PVTTF) (CSE: PVO) specialty pharmaceutical company with a focus on cardiovascular disease and overall health. Pivotal Therapeutics' lead product VASCAZEN® is a prescription only medical food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to levels associated with reduced risk of cardiovascular complications. OMAZEN® is a pharmaceutical grade Omega-3 providing over 90% pure Omega-3 in each capsule for the maintenance of good health. OMAZEN® is a patented product available for sale and distribution in Canada

Disclosure Notice
The information contained in this document is as of May 13, 2014. This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause Pivotal's actual results to differ materially from those projected in such forward-looking statements. These statements can be identified by the use of words such as "will", "anticipate", "estimate", "expect", "project", "forecast", "intend", "plan", "believe", "project", "potential", and similar expressions with any discussion of future operating or financial performance or events. In particular, factors that could cause actual results to differ materially from those in forward looking statements include the following: Pivotal's inability to obtain additional financing on acceptable terms; growth in costs and expenses; inability to compete with others who provide comparable products; risk that the Company's products will not gain widespread market acceptance; risks relating to the Company's ability to maintain its CSE listing. Forward-looking statements speak only as of the date made and are not guarantees of future performance. The Company undertakes no obligation to publicly update or revise any forward-looking statements contained in this document as a result of new information or future events or developments. CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this information.

SOURCE Pivotal Therapeutics Inc.

Image with caption: "VASCAZEN® a prescription only medical food for the dietary management of an Omega 3 deficiency in Cardiovascular patients. (CNW Group/Pivotal Therapeutics Inc.)". Image available at: http://photos.newswire.ca/images/download/20140513_C8112_PHOTO_EN_40243.jpg



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES